Improved early event-free survival with imatinib in Philadelphia chromosome - Positive acute lymphoblastic leukemia: A Children's Oncology Group Study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Piperazines
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Pyrimidines

abstract

  • Imatinib plus intensive chemotherapy improved 3-year EFS in children and adolescents with Ph+ ALL, with no appreciable increase in toxicity. BMT plus imatinib offered no advantage over BMT alone. Additional follow-up is required to determine the impact of this treatment on long-term EFS and determine whether chemotherapy plus imatinib can replace BMT.

publication date

  • November 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2773475

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.21.2514

PubMed ID

  • 19805687

Additional Document Info

start page

  • 5175

end page

  • 81

volume

  • 27

number

  • 31